Quantcast

Latest Head and neck cancer Stories

2012-05-17 14:18:12

Landmark research presented at annual cancer meeting Mount Sinai School of Medicine researchers will present several landmark studies, including data on treatment trends in late-stage cancer, a promising multiple myeloma vaccine, and predictive models of soft tissue sarcomas, prostate and bladder cancer, at the 2012 American Society of Clinical Oncology (ASCO) meeting June 1-5, 2012 in Chicago. Highlights of Mount Sinai research at ASCO: Age, Race, Lower Income, and Lack of...

2012-05-17 12:41:57

Screening lung cancer tumor samples for cancer-causing, or "driver," genetic mutations can help physicians tailor patients' treatments to target those specific mutations. While scientists have identified cancer-causing mutations for the majority of lung adenocarcinomas – the most common type of non-small cell lung cancer – and have developed drugs that can successfully address them, scientists have not yet identified targeted therapies for another type of non-small cell lung...

2012-05-17 09:26:40

Targeted therapies have been studied for years, but recent laboratory research is providing robust clues about drugs that might work better in combination, particularly in treating cancers that have become resistant to therapy. That kind of information is behind a novel clinical trial at Georgetown Lombardi Comprehensive Cancer Center that combines cetuximab and lapatinib. Findings from this phase I study will be presented at the American Society of Clinical Oncology annual meeting in...

2012-05-15 12:44:25

Researchers found that administering a common chemotherapy drug before bone tumors took root actually fertilized the bone marrow, enabling cancer cells, once introduced, to seed and grow more easily. The findings provide valuable insight as to why some cancers metastasize to bone, and could eventually result in new metastasis-prevention drugs, said Laurie McCauley, professor in the Department of Periodontics and Oral Medicine at the University of Michigan School of Dentistry and principal...

2012-05-11 14:23:09

Results from a randomized trial in head and neck cancer Patients with head and neck cancer and a low haemoglobin (Hb) level do not respond well to radiotherapy and therefore both control of their tumor and disease-free survival are compromised. Now researchers from The Netherlands have found that the problems caused by low Hb in these patients can be overcome by the use of a treatment known as ARCON therapy, in which accelerated radiotherapy is combined with carbogen (a mixture of carbon...

2012-05-10 09:42:25

New findings from a large Danish database of cancer patients suggest that, even though the human papilloma virus (HPV) can trigger throat cancer, patients who are HPV-positive and are light smokers, or don't smoke at all, have a good response to treatment using radiotherapy alone, without the addition of chemotherapy with its consequent toxic side-effects. Presenting her research at the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO 31) [1] today [Thursday],...

2012-05-10 09:27:31

Researchers believe they may have found a way to avoid damaging salivary glands during radiotherapy treatment for head and neck cancer — a discovery that could improve the quality of life of 500,000 patients a year worldwide with the disease. Presenting their findings to the 31st conference of the European Society for Radiotherapy and Oncology (ESTRO31) [1], the researchers said that they had discovered that the stem cells essential for regenerating the parotid gland (the largest...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.